The firm brings unique experience to tracking, assessing and explaining regulatory and reimbursement policy that affect the biopharmaceutical industry. The company’s goal is to advance mutual understanding among policymakers, business executives and the investment community, in the belief that a deeper understanding of policy leads to better business, and a deeper understanding of business leads to better policy.
Member Sign In:
- CFS/ME Draft Guidance Focuses on Symptom Alleviation; Highlights Areas for Potential Drug Development Tools Mar. 11, 2014
- Part D “Protected Classes” Stay Protected; CMS Drops Controversial Parts Of Rule, But Fraud Provisions To Proceed Mar. 10, 2014
- FDA Budget Request Calls For 8% Increase Over FY14: User Fees Make Up Over 90% of New Funds Mar. 07, 2014
See More Research Notes